DrugPatentWatch Database Preview

Details for Patent: 7,732,490

« Back to Dashboard

Which drugs does patent 7,732,490 protect, and when does it expire?

Patent 7,732,490 protects ZOLINZA and is included in one NDA.

This patent has eighty-six patent family members in twenty-eight countries.

Summary for Patent: 7,732,490

Title:	Methods of treating cancer
Abstract:	The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
Inventor(s):	Richon; Victoria M. (Rye, NY), Chiao; Judy H. (Berkeley Heights, NJ), Kelly; William Kevin (Scotch Plains, NJ), Miller; Thomas A. (Brookline, MA)
Assignee:	Merck HDAC Research, LLC (Boston, MA) Sloan-Kettering Institute for Cancer Research (New York, NY)
Application Number:	11/853,700
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 7,732,490

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Merck	ZOLINZA	vorinostat	CAPSULE;ORAL	021991-001	Oct 6, 2006		RX	Yes	Yes						TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)

Non-Orange Book US Patents Family Members for Patent 7,732,490

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
8,101,663	Polymorphs of suberoylanilide hydroxamic acid
7,851,509	Polymorphs of suberoylanilide hydroxamic acid
7,399,787	Methods of treating cancer with HDAC inhibitors
7,456,219	Polymorphs of suberoylanilide hydroxamic acid

International Patents Family Members for US Patent 7,732,490

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	462426
Australia	2003213684
Australia	2004266169
Australia	2004283717